0 CHECKOUT

Birch Pollen Allergy - Pipeline Review, H1 2015

  • ID: 3099746
  • January 2015
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Stallergenes S.A.
  • MORE

Birch Pollen Allergy - Pipeline Review, H1 2015

Summary

This, ‘Birch Pollen Allergy - Pipeline Review, H1 2015’, provides an overview of the Birch Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Stallergenes S.A.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Birch Pollen Allergy Overview
Therapeutics Development
Pipeline Products for Birch Pollen Allergy - Overview
Pipeline Products for Birch Pollen Allergy - Comparative Analysis
Birch Pollen Allergy - Therapeutics under Development by Companies
Birch Pollen Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Birch Pollen Allergy - Products under Development by Companies
Birch Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
HAL Allergy BV
Stallergenes S.A.
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AllerT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch-SPIRE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Birch Pollen Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1-FV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergy - Recent Pipeline Updates
Birch Pollen Allergy - Dormant Projects
Birch Pollen Allergy - Discontinued Products
Birch Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Birch Pollen Allergy, H1 2015
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2015
Birch Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015
Birch Pollen Allergy - Pipeline by Anergis SA, H1 2015
Birch Pollen Allergy - Pipeline by Biomay AG, H1 2015
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2015
Birch Pollen Allergy - Pipeline by Stallergenes S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2015
Birch Pollen Allergy - Dormant Projects, H1 2015
Birch Pollen Allergy - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Birch Pollen Allergy, H1 2015
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
HAL Allergy BV
Stallergenes S.A.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare